๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The risk of secondary malignancies over 30 years after the treatment of non-hodgkin lymphoma

โœ Scribed by Linda Morris Brown; Regan A. Howard; Lois B. Travis


Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
52 KB
Volume
107
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


The Risk of Secondary Malignancies Over 30 Years After the Treatment of Non-Hodgkin Lymphoma T ward et al. 1 reported a significantly elevated risk of mesothe- lioma in a population-based study of survivors of non-Hodgkin lymphoma who were treated with radiation. Although the authors were not aware of other population-based studies that describe an increased risk of mesothelioma after irradiation, we reported a significantly elevated relative risk (RR) of mesothelioma among irradiated testicular cancer patients (RR, 4.0; 95% confidence interval [95% CI], 2.0-8.1; 14 cases). 2 Herein, we provide to our knowledge the first description of significant excesses of mesothelioma (40 cases) among 376,825 breast cancer patients who had survived for 1 year and were reported to population-based cancer registries in Sweden, Denmark, Finland, and Norway between January 1, 1943 and December 31, 2002. The estimated average doses of radiation received by the ipsilateral lung/pleura range from 15.1 to 15.5 gray (Gy) based on the standard tangential (medial and lateral) and anterior supraclavicular treatment fields (that delivered a tumor dose of 40 to 50 Gy) used to treat breast cancer during the study period.

We found a significantly elevated risk of mesothelioma (standard incidence ratio [SIR] of 1.42; 95% CI, 1.02-1.94). Excesses began 10 years after a diagnosis of breast cancer, with the highest risk (SIR of 5.60; 95% CI, 2.05-12.21; 6 patients) observed at 30 years of follow-up, a temporal pattern that was consistent with the late effects of radiation. Risk was most pronounced for women diagnosed before 1970 (SIR of 2.46; 95% CI, 1.51-3.81; 20 cases). SIRs for the subset of 22 breast cancer patients reported to registries that record treatment data were 1.78 (95% CI, 1.00-2.95; 15 cases) for those who initially received radiotherapy compared with 0.95 (95% CI, 0.38-1.97; 7 cases) for whom radiotherapy was not recorded. Treatment regimens for breast cancer have undergone substantial changes over the past several decades, and therefore the evaluation of long-term survivors often reflects the effects of therapies that have subsequently been modified. Nonetheless, our findings add to the growing body of evidence that large doses of radiation might be associated with excess mesotheliomas, although analytic studies are required to establish a causal relation.


๐Ÿ“œ SIMILAR VOLUMES


Treatment of aggressive non-hodgkin's ly
โœ Richard I. Fisher ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 538 KB

Therapy for aggressive non-Hodgkin's lymphomas has undergone significant evolution in the last 25 years. First generation combination chemotherapy studies produced complete remissions (CRs) of 45-53%, with 30-37% long term survivors. New treatment programs aimed at increasing CR rates were then deve

Non-Hodgkin's lymphoma of the head and n
โœ Rakesh M. Nathu; Nancy Price Mendenhall; Nidal M. Almasri; James W. Lynch ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 147 KB ๐Ÿ‘ 2 views

Background. Outcome in previously untreated patients with non-Hodgkin's lymphoma of the head and neck needed to be assessed. Methods. A retrospective review was performed of 79 patients with stage I or II non-Hodgkin's lymphoma of the head and neck treated between 1964 and 1994 with radiotherapy (R